Status:
COMPLETED
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Diabetic Neuropathy, Painful
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twi...
Eligibility Criteria
Inclusion
- Adults with Type 1 or 2 diabetes
- Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months
Exclusion
- Patients must not be in poor or unstable health.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT00159679
Start Date
September 1 2004
End Date
October 1 2005
Last Update
January 25 2021
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hot Springs, Arkansas, United States, 71913
2
Pfizer Investigational Site
La Jolla, California, United States, 92037
3
Pfizer Investigational Site
Torrance, California, United States, 90502
4
Pfizer Investigational Site
Torrance, California, United States, 90509